According to Zhitong Finance APP, Goldman Sachs released a research report stating a "buy" rating for CSPC Pharma (01093), with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 more BD transactions within 2024, emphasizing continuous review of the product line, strengthening business expansion efforts. The bank expects more transactions to occur in the future.

The bank pointed out that CSPC Pharma announced plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein(a) in the preclinical stage) and any products containing YS2302018 globally. This marks the company's first collaboration with Astrazeneca, seen as an important step in the company's global expansion process.